The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Predicting in vivo drug interactions from in vitro drug discovery data
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Cytochrome P-450: Structure, Mechanism, and Biochemistry
(1986) · Springer eBooks · doi:10.1007/978-1-4757-9939-2 · Cited by 727
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400293200 · Cited by 705
Arzneimittelforschung: Durch Innovationen zum Markterfolg
Sedlacek, H.-H. (2015) · De Gruyter eBooks · doi:10.1515/9783110403527 · Cited by 699
Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms
Porter, T. D., & Coon, M. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92717-1 · Cited by 678
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfleld, G. M., Miners, J. O., Birkett, D. J., & Goldstein, J. A. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00007 · Cited by 582
Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., & Tracy, T. S. (1998) · Biochemistry · doi:10.1021/bi9715627 · Cited by 511
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., & Korzekwa, K. R. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00005 · Cited by 485
Self-citationPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution
Wester, M. R., Yano, J. K., Schoch, G. A., Yang, C., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405427200 · Cited by 440
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00409-5 · Cited by 423
[10] Mechanism-based enzyme inactivators
Silverman, R. B. (1995) · Methods in Enzymology · doi:10.1016/0076-6879(95)49038-8 · Cited by 384
Cooperativity in Oxidations Catalyzed by Cytochrome P450 3A4
Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., & Guengerich, F. P. (1997) · Biochemistry · doi:10.1021/bi962359z · Cited by 383
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.
Rane, A., Wilkinson, G. R., & Shand, D. G. (1977) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30786-x · Cited by 328
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Oxidation of quinidine by human liver cytochrome P-450.
Guengerich, F. P., Müller-Enoch, D., & Blair, I. A. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10372-6 · Cited by 304
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Role of Cytochrome P450 Enzymes in Drug-Drug Interactions
Guengerich, F. P. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60200-8 · Cited by 284
Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., & Sugiyama, Y. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 278
Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13672-0 · Cited by 273
Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes
Hollenberg, P. F. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001387 · Cited by 243
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999) · JAMA · doi:10.1001/jama.281.18.1728 · Cited by 238
Dierks, E. A., Stams, K. R., Lim, H., Cornelius, G., Zhang, H., & Ball, S. E. (2001) · PubMed · Cited by 236
Hickman, D., Wang, J. P., Wang, Y., & Unadkat, J. D. (1998) · PubMed · Cited by 222
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline
Kunze, K. L., & Trager, W. F. (1993) · Chemical Research in Toxicology · doi:10.1021/tx00035a009 · Cited by 216
Kinetics of drug-drug interactions
Rowland, M., & Matin, S. B. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059791 · Cited by 208
Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
Schwarz, U. I. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.6.x · Cited by 170
Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions: A Critical Review of the Evidence
Sproule, B. A., Naranjo, C. A., Bremner, K. E., & Hassan, P. C. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733060-00004 · Cited by 169
Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models
Venkatakrishnan, K., von Moltke, L., Obach, R., & Greenblatt, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489361 · Cited by 162
Heterotropic Cooperativity of Cytochrome P450 3A4 and Potential Drug-Drug Interactions
Tang, W., & Stearns, R. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338658 · Cited by 162
Kunze, K. L., Wienkers, L. C., Thummel, K. E., & Trager, W. F. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07368-4 · Cited by 161
Self-citationPharmacokinetics and metabolism in early drug discovery
Smith, D. A., & Waterbeemd, H. V. D. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80056-8 · Cited by 160
Ito, K., Ogihara, K., Kanamitsu, S.-I., & Itoh, T. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.945 · Cited by 151
Shou, M., Qin, M. E. I., ETTORE, J. M. W., Dai, R., Baillie, T. A., & Rushmore, T. H. (1999) · Biochemical Journal · doi:10.1042/bj3400845 · Cited by 148
Moody, G. C., Griffin, S. J., Mather, A. N., McGinnity, D. F., & Riley, R. J. (1999) · Xenobiotica · doi:10.1080/004982599238812 · Cited by 146
Wang, R. W., Newton, D. J., Scheri, T. D., & Lu, A. Y. H. (1997) · PubMed · Cited by 141
Donato, M. T., & Castell, J. V. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00004 · Cited by 138
Margolis, J. M., & Obach, R. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.606 · Cited by 135
Obach, R. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08404-1 · Cited by 134
Enzyme Kinetics of Cytochrome P450-Mediated Reactions
Shou, M., Lin, Y. J., Lü, P., Tang, C., Mei, Q., Cui, D., Tang, W., Ngui, J. S., Lin, C., Singh, R., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200013338784 · Cited by 121
Mechanism-based inactivators as probes of cytochrome P450 structure and function
Kent, U., Jushchhyshyn, M., & Hollenberg, P. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338478 · Cited by 113
Janiszewski, J. S., Rogers, K. J., Whalen, K. M., Cole, M. J., Liston, T. E., Duchoslav, E., & Fouda, H. G. (2001) · Analytical Chemistry · doi:10.1021/ac0013251 · Cited by 103
Chauret, N., Tremblay, N. M., Lackman, R. L., et al. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4348 · Cited by 96
“Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science?
Zhou, H., Tong, Z., & McLeod, J. F. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003261333 · Cited by 87
Byrdwell, W. C. (1998) · Rapid Communications in Mass Spectrometry · doi:10.1002/(sici)1097-0231(19980314)12:5<217::aid-rcm146>3.0.co;2-i · Cited by 82
Siebert, G. A., Hung, D. Y., Chang, P., & Roberts, M. S. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056770 · Cited by 77
Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding Domains
Schrag, M. L., & Wienkers, L. C. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2401 · Cited by 76
Self-citationConformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy
Davydov, D. R., Halpert, J. R., Renaud, J., & Hoa, G. H. B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.247 · Cited by 74
Inhibition‐Based Metabolic Drug–Drug Interactions: Predictions from In Vitro Data
Yao, C., & Levy, R. H. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10179 · Cited by 74
Kim, K., Ahn, T., & Yun, C. (2003) · Biochemistry · doi:10.1021/bi035280k · Cited by 69
Tracy, T. S. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489280 · Cited by 65
Sense and Nonsense in the Prediction of Drug-Drug Interactions
Lin, J. H. (2000) · Current Drug Metabolism · doi:10.2174/1389200003338947 · Cited by 62
Triazolam Substrate Inhibition
Schrag, M. L., & Wienkers, L. C. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0667-6_56 · Cited by 61
Self-citationGao, F., Johnson, D. L., Ekins, S., Janiszewski, J. S., Kelly, K. G., Meyer, R. D., & West, M. (2002) · SLAS DISCOVERY · doi:10.1177/108705710200700410 · Cited by 57
Topological Alteration of the CYP3A4 Active Site by the Divalent Cation Mg2+
Schrag, M. L., & Wienkers, L. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12050-0 · Cited by 46
Self-citationJushchyshyn, M. I., Hutzler, J. M., Schrag, M. L., & Wienkers, L. C. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2005.02.027 · Cited by 42
Self-citationWienkers, L. C., Steenwyk, R. C., Sanders, P. E., & Pearson, P. G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12957-1 · Cited by 41
Self-citationGemzik, B., Halvorson, M. R., & Parkinson, A. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90251-m · Cited by 38
Shen, L., Fitzloff, J. F., & Cook, C. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.186 · Cited by 37
Strobel, S. M., Szklarz, G. D., He, Y., Foroozesh, M. K., Alworth, W. L., Roberts, E. S., Hollenberg, P. F., & Halpert, J. R. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34919-5 · Cited by 35
Saito, M., Hirata‐Koizumi, M., Urano, T., Miyake, S., & Hasegawa, R. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00605.x · Cited by 33
Neal, J. M., Kunze, K. L., Levy, R. H., O’Reilly, R. A., & Trager, W. F. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1043 · Cited by 30
Hutzler, J. M., Powers, F. J., Wynalda, M. A., & Wienkers, L. C. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00350-3 · Cited by 28
Self-citationEvaluation of Methods for Predicting Drug-drug Interactions by Monte Carlo Simulation
Kato, M., Tachibana, T., Ito, K., & Sugiyama, Y. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.121 · Cited by 26
Fleishaker, J. C., Pearson, P. G., Wienkers, L. C., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12958-3 · Cited by 25
Self-citationWienkers, L. C. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00002-7 · Cited by 15
Self-citation
Cited by
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Cytochrome P450s and other enzymes in drug metabolism and toxicity
Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 624
Targeting Aldehyde Dehydrogenase 2: New Therapeutic Opportunities
Chen, C.-H., Ferreira, J. C. B., Gross, E. R., & Mochly-Rosen, D. (2014) · Physiological Reviews · doi:10.1152/physrev.00017.2013 · Cited by 614
Metadata
- Authors
- Wienkers, L. C., & Heath, T. G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-10
- Volume
- 4
- Issue
- 10
- Pages
- 825-833
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1992475241
- Cited by
- 904
- References
- 82
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.